Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.
Saved in:
| Title: | Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis. |
|---|---|
| Authors: | Poveda, A.1 (AUTHOR) apoveda@initiaoncologia.com, Lheureux, S.2 (AUTHOR), Colombo, N.3 (AUTHOR), Cibula, D.4 (AUTHOR), Lindemann, K.5 (AUTHOR), Weberpals, J.6 (AUTHOR), Bjurberg, M.7 (AUTHOR), Oaknin, A.8 (AUTHOR), Sikorska, M.9 (AUTHOR), González-Martín, A.10 (AUTHOR), Madry, R.11 (AUTHOR), Pérez, M.J. Rubio12 (AUTHOR), Ledermann, J.13 (AUTHOR), Davidson, R.1,14 (AUTHOR), Blakeley, C.1,14 (AUTHOR), Bennett, J.1,14 (AUTHOR), Barnicle, A.14 (AUTHOR), Škof, E.15 (AUTHOR) |
| Source: | Gynecologic Oncology. Mar2022, Vol. 164 Issue 3, p498-504. 7p. |
| Database: | Academic Search Ultimate |
| ISSN: | 00908258 |
|---|---|
| DOI: | 10.1016/j.ygyno.2021.12.025 |
